The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Yu, Yi ^a   Edassery, Seby L ^a   Barua, Animesh ^a   Abramowicz, Jacques S ^a   Bahr, Janice M ^b   Hellstrom, Ingegerd ^c   Luborsky, Judith L ^a  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Animal Model; Hens; Mesothelin; Mesothelin antibodies; Ovarian Cancer

Indexed keywords

AUTOANTIBODY; MESOTHELIN; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 79960852222     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-12     Document Type: Article

References (53)

1. The immunologists' debt to the chicken. Davison TF, Br Poult Sci 2003 44 6 21 12737220 (Pubitemid 37399797)
2. Ovarian tumors of the hen. Fredrickson TN, Environ Health Perspect 1987 73 35 51 3665870
3. Dietary aspirin decreases the stage of ovarian cancer in the hen. Urick ME, Giles JR, Johnson PA, Gynecol Oncol 2009 112 166 170 10.1016/j.ygyno.2008. 09.032 18986688
4. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, et al. Cancer Prev Res (Phila) 2009 2 114 121 10.1158/1940-6207.CAPR-08-0065
5. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL, Int J Gynecol Cancer 2009 19 531 539 10.1111/IGC.0b013e3181a41613 19509547
6. Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus). Hales DB, Zhuge Y, Lagman JA, Ansenberger K, Mahon C, Barua A, Luborsky JL, Bahr JM, Endocrine 2008 33 235 244 10.1007/s12020-008-9080-z 18498063
7. Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma. Hawkridge AM, Wysocky RB, Petitte JN, Anderson KE, Mozdziak PE, Fletcher OJ, Horowitz JM, Muddiman DC, Anal Bioanal Chem 398 737 749
8. Comparison of gene expression patterns between avian and human ovarian cancers. Gonzalez Bosquet J, Peedicayil A, Maguire J, Chien J, Rodriguez GC, Whitaker R, Petitte JN, Anderson KE, Barnes HJ, Shridhar V, Cliby WA, Gynecol Oncol 120 256 264
9. Animal models of ovarian cancer. Vanderhyden BC, Shaw TJ, Ethier JF, Reprod Biol Endocrinol 2003 1 67 10.1186/1477-7827-1-67 14613552 (Pubitemid 39130458)
10. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Rodriguez-Burford C, Barnes MN, Berry W, Partridge EE, Grizzle WE, Gynecol Oncol 2001 81 373 379 10.1006/gyno.2001.6191 11371125 (Pubitemid 32494650)
11. CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Jackson E, Anderson K, Ashwell C, Petitte J, Mozdziak PE, Gynecol Oncol 2007 104 192 198 10.1016/j.ygyno.2006.07.024 16942793 (Pubitemid 46054125)
12. Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Stammer K, Edassery SL, Barua A, Bitterman P, Bahr JM, Hales DB, Luborsky JL, Gynecol Oncol 2008 109 115 121 10.1016/j.ygyno.2007.12.030 18272210
13. Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer. Urick ME, Johnson PA, Gynecol Oncol 2006 103 673 678 10.1016/j.ygyno.2006.05.012 16797680 (Pubitemid 44602185)
14. E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM, Hales DB, Gynecol Oncol 2009 113 362 369 10.1016/j.ygyno.2009.02.011 19321195
15. VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. Urick ME, Giles JR, Johnson PA, Gynecol Oncol 2008 110 418 424 10.1016/j.ygyno.2008.05.018 18606441
16. Detection of tumor-associated neoangiogenesis by Doppler ultrasonography during early-stage ovarian cancer in laying hens: a preclinical model of human spontaneous ovarian cancer. Barua A, Bitterman P, Bahr JM, Bradaric MJ, Hales DB, Luborsky JL, Abramowicz JS, J Ultrasound Med 29 173 182
17. CYP1B1 expression in ovarian cancer in the laying hen Gallusdomesticus. Zhuge Y, Lagman JA, Ansenberger K, Mahon CJ, Daikoku T, Dey SK, Bahr JM, Hales DB, Gynecol Oncol 2009 112 171 178 10.1016/j.ygyno.2008.09.026 18973935
18. Anti-ovarian and anti-tumor antibodies in women with ovarian cancer. Barua A, Bradaric MJ, Kebede T, Espinosa S, Edassery SL, Bitterman P, Rotmensch J, Luborsky JL, Am J Reprod Immunol 2007 57 243 249 10.1111/j.1600-0897.2007. 00470.x 17362385 (Pubitemid 46394836)
19. Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Barua A, Edassery SL, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Luborsky JL, Int J Gynecol Cancer 2009 19 500 507 10.1111/IGC.0b013e3181a39db1 19509543
20. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, Pastan I, Proc Natl Acad Sci USA 1996 93 136 140 10.1073/pnas.93.1.136 8552591 (Pubitemid 26041483)
21. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM, Hum Pathol 2003 34 605 609 10.1016/S0046-8177(03)00177-1 12827615 (Pubitemid 36750373)
22. Application of mesothelin immunostaining in tumor diagnosis. Ordonez NG, Am J Surg Pathol 2003 27 1418 1428 10.1097/00000478-200311000-00003 14576474 (Pubitemid 37315193)
23. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Chang K, Pastan I, Int J Cancer 1994 57 90 97 10.1002/ijc.2910570117 8150545 (Pubitemid 24117106)
24. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ, Cancer Res 2000 60 6281 6287 11103784
25. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, et al. Clin Cancer Res 2001 7 3862 3868 11751476 (Pubitemid 34044602)
26. Mesothelin targeted cancer immunotherapy. Hassan R, Ho M, Eur J Cancer 2008 44 46 53 10.1016/j.ejca.2007.08.028 17945478 (Pubitemid 350262830)
27. Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors. Obulhasim G, Fujii H, Matsumoto T, Yasen M, Abe M, Matsuoka S, Ohtsuji N, Hino O, Eur J Gynaecol Oncol 2010 31 63 71 20349783
28. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. Muminova ZE, Strong TV, Shaw DR, BMC Cancer 2004 4 19 10.1186/1471-2407-4-19 15140265 (Pubitemid 38851354)
29. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Zhang Y, Pastan I, Clin Cancer Res 2008 14 7981 7986 10.1158/1078-0432.CCR-08-0324 19088013
30. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr, Gynecol Oncol 2005 99 267 277 10.1016/j.ygyno.2005.06.040 16061277 (Pubitemid 41502830)
31. Mesothelin: a new target for immunotherapy. Hassan R, Bera T, Pastan I, Clin Cancer Res 2004 10 3937 3942 10.1158/1078-0432.CCR-03-0801 15217923 (Pubitemid 38812466)
32. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE, Cancer Epidemiol Biomarkers Prev 2006 15 1014 1020 10.1158/1055-9965.EPI-05-0334 16702385 (Pubitemid 43823532)
33. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I, Clin Cancer Res 2005 11 3814 3820 10.1158/1078-0432.CCR-04-2304 15897581 (Pubitemid 40685601)
34. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M, Clin Cancer Res 2006 12 447 453 10.1158/1078-0432.CCR-05-1477 16428485 (Pubitemid 43166134)
35. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, et al. Cancer Epidemiol Biomarkers Prev 2008 17 1520 1526 10.1158/1055-9965.EPI-08-0039 18559570
36. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I, Gynecol Oncol 2004 95 9 15 10.1016/j.ygyno.2004.07. 039 15385104 (Pubitemid 39286271)
37. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA, Anticancer Res 2006 26 4721 4728 17214332
38. Control of human mesothelin-expressing tumors by DNA vaccines. Chang CL, Wu TC, Hung CF, Gene Ther 2007 14 1189 1198 10.1038/sj.gt.3302974 17581599 (Pubitemid 47215422)
39. Vaccines to treat cancer - an old approach whose time has arrived. Hellstrom KE, Hellstrom I, J Cell Biochem 2007 102 291 300 10.1002/jcb.21468 17729239 (Pubitemid 47519403)
40. Mesothelin is not required for normal mouse development or reproduction. Bera TK, Pastan I, Mol Cell Biol 2000 20 2902 2906 10.1128/MCB.20.8.2902-2906. 2000 10733593 (Pubitemid 30183509)
41. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N, Cancer Lett 2007 247 130 136 10.1016/j.canlet.2006.03.029 16677756 (Pubitemid 44959415)
42. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A, J Biol Chem 2004 279 9190 9198 10.1074/jbc.M312372200 14676194 (Pubitemid 38295982)
43. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, et al. Mol Cancer 2006 5 50 10.1186/1476-4598-5-50 17067392 (Pubitemid 44742657)
44. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer. McLemore MR, Aouizerat B, Biol Res Nurs 2005 6 262 267 10.1177/1099800404274445 15788735 (Pubitemid 44289595)
45. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Goodman MT, Howe HL, Cancer 2003 97 2615 2630 10.1002/cncr.11339 12733127 (Pubitemid 36539063)
46. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Goodman MT, Correa CN, Tung KH, Roffers SD, Cheng Wu X, Young JL, Wilkens LR, Carney ME, Howe HL, Cancer 2003 97 2648 2659 10.1002/cncr.11347 12733130 (Pubitemid 36539066)
47. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Lu KH, Yates MS, Mok SC, Cancer Prev Res (Phila) 2009 2 773 775 10.1158/1940-6207.CAPR-09-0156
48. A genetically defined model for human ovarian cancer. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et al. Cancer Res 2004 64 1655 1663 10.1158/0008-5472.CAN-03-3380 14996724 (Pubitemid 38428686)
49. Rodent models for ovarian cancer research. Stakleff KD, Von Gruenigen VE, Int J Gynecol Cancer 2003 13 405 412 10.1046/j.1525-1438.2003.13317.x 12911715 (Pubitemid 38220657)
50. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T, Nat Med 2005 11 63 70 10.1038/nm1173 15619626 (Pubitemid 40215839)
51. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, Yamaguchi N, J Biol Chem 1995 270 21984 21990 10.1074/jbc.270.37.21984 7665620
52. Localization of mesothelin in epithelial ovarian cancer. Hassan R, Kreitman RJ, Pastan I, Willingham MC, Appl Immunohistochem Mol Morphol 2005 13 243 247 10.1097/01.pai.00000141545.36485.d6 16082249 (Pubitemid 41209017)
53. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Ordonez NG, Mod Pathol 2003 16 192 197 10.1097/01.MP.0000056981.16578.C3 12640097 (Pubitemid 36337423)